id: NEW:her2_low_tumor_status_to_NEW:breast_cancer_progression
name: HER2-Low Tumor Status â†’ Breast Cancer Progression
from_node:
  node_id: NEW:her2_low_tumor_status
  node_name: HER2-Low Tumor Status
to_node:
  node_id: NEW:breast_cancer_progression
  node_name: Breast Cancer Progression
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: HER2-low expression (IHC 1+ or IHC 2+/ISH-) represents a distinct biological subtype of hormone
  receptor-positive breast cancer'
- 'Step 2: Low-level HER2 expression may confer reduced sensitivity to CDK 4/6 inhibitor therapy through
  altered cell cycle regulation'
- 'Step 3: Diminished CDK 4/6 inhibitor efficacy leads to continued tumor cell proliferation and disease
  progression'
- 'Step 4: Higher progression-free survival hazard indicates faster disease advancement compared to HER2-zero
  tumors'
evidence:
  quality_rating: A
  n_studies: 9
  primary_citation: 'D. Guven and TK Sahin 2024. "The association between HER2-low status and survival
    in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors:
    a systematic review and meta-analysis." https://doi.org/10.1007/s10549-023-07226-1'
  supporting_citations:
  - Additional citations require full-text access - meta-analysis included 9 studies
  - Studies searched from Pubmed, Web of Science, and Scopus databases
  - Studies included MBC patients treated with CDK 4/6 inhibitors reporting survival outcomes by HER2
    expression
  doi: 10.1007/s10549-023-07226-1
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: HER2-low tumor status is associated with a 22% higher risk of progression and/or death compared
  to HER2-zero tumors in patients with hormone receptor-positive metastatic breast cancer treated with
  CDK 4/6 inhibitors. This suggests HER2-low may be a biomarker for reduced treatment efficacy.
quantitative_effects:
  effect_size:
    value: 1.22
    type: hazard_ratio
    ci_lower: 1.1
    ci_upper: 1.35
  p_value: 0.001
  sample_size: 2705
moderators:
- name: CDK 4/6 inhibitor treatment
  direction: strengthens
  strength: strong
  description: The differential effect is observed specifically in the context of CDK 4/6 inhibitor treatment
    for HR+ metastatic breast cancer
structural_competency:
  equity_implications: This is primarily a biological/clinical mechanism rather than a structural determinant.
    However, recognition of HER2-low as a distinct category with treatment implications has healthcare
    access implications - patients may benefit from alternative therapeutic strategies, and access to
    HER2-targeting agents (like trastuzumab deruxtecan) may become relevant for this population. Equity
    considerations include whether biomarker testing and newer targeted therapies are equally accessible
    across demographic groups.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.890424'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
